The NLRP3 (NOD-like receptor family pyrin domain containing 3) inflammasome is a key cytosolic protein complex that drives neuroinflammation through activation of caspase-1 and subsequent production of pro-inflammatory cytokines interleukin-1β (IL-1β) and interleukin-18 (IL-18)[1]. Growing evidence implicates NLRP3 inflammasome activation as a common pathological mechanism across multiple neurodegenerative diseases, making it an attractive therapeutic target[2].
The NLRP3 inflammasome consists of three components:
Activation signals in the brain include:
Active NLRP3 inflammasome produces:
Multiple studies demonstrate that amyloid-beta (Aβ) plaques directly activate the NLRP3 inflammasome in microglia:
NLRP3 inhibition may provide benefits through:
In PD, mitochondrial dysfunction is a key trigger:
ALS features prominent neuroinflammation:
FTD with TDP-43 pathology (FTD-TDP) shows:
FTD shares inflammatory pathways with ALS, suggesting common therapeutic approaches may be effective.
CBS and PSP represent significant unmet needs:
Evidence is emerging:
MCC950 is a potent small-molecule NLRP3 inhibitor:
Dapansutrile is an oral NLRP3 inhibitor in clinical trials:
Colchicine has broad anti-inflammatory effects:
The blood-brain barrier (BBB) presents a major challenge:
NLRP3 inhibitors may synergize with:
Given the complex biology:
Swanson, K.V., Deng, M. & Ting, J.P. The NLRP3 inflammasome: molecular activation and regulation. Nat Rev Immunol. 2019. ↩︎
Liu, L. & Chan, C. The role of NLRP3 inflammasome in Alzheimer's disease and potential therapeutic targets. Front Pharmacol. 2021. ↩︎
Heneka, M.T. et al. NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. Nature. 2013. ↩︎ ↩︎ ↩︎
Mao, Z. et al. NLRC4 mediates TLR2-induced neuroinflammation through the PI3K/Akt signaling pathway in Parkinson's disease models. J Neuroinflammation. 2018. ↩︎ ↩︎ ↩︎
Cheroni, C. et al. TDP-43 loss-of-function drives aberrant NLRP3 inflammasome activation in microglia. Acta Neuropathol. 2023. ↩︎ ↩︎ ↩︎
Heneka, M.T. et al. Mutant huntingtin fragment selectively induces NLRP3 inflammasome activation in Huntington's disease. Mol Brain. 2023. ↩︎ ↩︎ ↩︎
Shaftel, S.S. et al. Chronic interleukin-1β expression in mouse brain leads to hydrocephalus and deficits in working and social interaction. J Neurosci. 2008. ↩︎ ↩︎ ↩︎
Alboni, S. et al. Interleukin-18 in the CNS. J Neuroinflammation. 2011. ↩︎
Nakahira, K. et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NLRP3 inflammasome. Nat Immunol. 2011. ↩︎
Codolo, G. et al. Triggering of inflammasome by aggregated α-synuclein, an inflammatory response in synucleinopathies. PLoS One. 2013. ↩︎ ↩︎
Blum-Degen, D. et al. [Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and Parkinson's disease patients](https://doi.org/10.1016/0304-3940(95). Neurosci Lett. 1995. ↩︎
Zhang, P. et al. NLRP3 polymorphisms are associated with Parkinson's disease in a Chinese Han population. Neurosci Lett. 2018. ↩︎
Johann, S. et al. NLRP3 inflammasome is activated in motor neurons of a genetic mouse model of ALS. Cell Mol Neurobiol. 2015. ↩︎ ↩︎
Brown, M.A. et al. UNC13A contributes to ALS through effects on NLRP3 inflammasome. Nat Neurosci. 2023. ↩︎
Oda, A. et al. TDP-43 and NLRP3 inflammasome in frontotemporal dementia with TDP-43 pathology. J Neuroinflammation. 2022. ↩︎
Wang, B. et al. Necroptosis in neurodegenerative diseases: a potential therapeutic target. Cell Death Dis. 2020. ↩︎
Boxer, A.L. et al. [Frontotemporal dementia: new emerging therapies](https://doi.org/10.1016/S1474-4422(23). Lancet Neurol. 2023. ↩︎
Chen, Y. et al. NLRP3 deficiency attenuates Huntington's disease pathology in R6/2 mice. Brain. 2022. ↩︎
Coll, R.C. et al. MCC950 directly targets the NLRP3 ATP-hydrolysis domain for rapid inflammasome inhibition. Nat Chem Biol. 2015. ↩︎ ↩︎ ↩︎
Tam, H.K. et al. Strategies to improve brain penetration of NLRP3 inhibitors. J Med Chem. 2024. ↩︎ ↩︎ ↩︎
Marchetti, C. et al. OLT1177 (dapansutrile), a novel NLRP3 inhibitor, attenuates inflammation and tissue damage in an in vivo model of gout. Arthritis Rheumatol. 2018. ↩︎ ↩︎ ↩︎ ↩︎
Leung, Y.Y. et al. Colchicine for osteoarthritis. Cochrane Database Syst Rev. 2021. ↩︎ ↩︎ ↩︎ ↩︎
Lamkanfi, M. et al. Glyburide inhibits the NLRP3 inflammasome. Nat Chem Biol. 2009. ↩︎
Zhang, J. et al. Natural products as modulators of NLRP3 inflammasome: a systematic review. Phytother Res. 2021. ↩︎
Deczkowska, A. et al. TREM2: a clustering receptor for microglial phagocytosis in the CNS. Nat Rev Neurosci. 2020. ↩︎
Sharif, H. et al. Structural mechanism for NEK7-licensed activation of NLRP3 inflammasome. Nature. 2019. ↩︎
Ridker, P.M. et al. Canakinumab for the treatment of chronic inflammation. Nat Rev Drug Discov. 2021. ↩︎
Tronel, C. et al. TSPO PET imaging: a new tool for studying neuroinflammation in neurodegenerative diseases. J Neuroinflammation. 2022. ↩︎